Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: Neuropsychiatric safety and relative efficacy of varenicline, bupropion, and transdermal nicotine patch (NRT) in those with psychiatric disorders are of interest. Methods: We performed secondary analyses of safety and efficacy outcomes by psychiatric diagnosis in EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study), a 12-week, randomized, double-blind, triple-dummy, placebo- and active (NRT)–controlled trial of varenicline and bupropion with 12-week follow-up, in a subset population, n = 4092, with a primary psychotic (n = 390), anxiety (n = 792), or mood (n = 2910) disorder. Primary end-point parameters were incidence of prespecified moderate and severe neuropsychiatric adverse events (NPSAEs) and weeks 9 to 12 continuous abstinence rates (9–12CAR). Results: The observed NPSAE incidence across treatments was 5.1% to 6.3% in those with a psychotic disorder, 4.6% to 8.0% in those with an anxiety disorder, and 4.6% to 6.8% in those with a mood disorder. Neither varenicline nor bupropion was associated with significantly increased NPSAEs relative to NRT or placebo in the psychiatric cohort or any psychiatric diagnostic subcohort. There was a significant effect of treatment on 9–12CAR (P < 0.0001) and no significant treatment-by-diagnostic subcohort interaction (P = 0.24). Abstinence rates with varenicline were superior to bupropion, NRT, and placebo, and abstinence with bupropion and NRT was superior to placebo. Within-diagnostic subcohort comparisons of treatment efficacy yielded estimated odds ratios for 9–12CAR versus placebo of greater than 3.00 for varenicline, greater than 1.90 for bupropion, and greater than 1.80 for NRT for all diagnostic groups. Conclusions: Varenicline, bupropion, and nicotine patch are well tolerated and effective in adults with psychotic, anxiety, and mood disorders. The relative effectiveness of varenicline, bupropion, and NRT versus placebo did not vary across psychiatric diagnoses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 3×
“Table 2 presents the observed incidence of the primary NPS end point, its 16 components, and Supplemental Table 1, Supplemental Digital Content 2, http://links.lww.com/JCP/A553, presents NPS events that were severe, that were serious adverse events (SAEs), or that led to treatment discontinuation, as well as suicidal…”
Influential21st-Century Hazards of Smoking and Benefits of Cessation in the United States
Jha, P., Ramasundarahettige, C., Landsman, V., Rostron, B., Thun, M., Anderson, R. N., McAfee, T., & Peto, R. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1211128 · Cited by 1,767
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Anthenelli, R. M., Benowitz, N. L., West, R., St Aubin, L., McRae, T., Lawrence, D., Ascher, J., Russ, C., Krishen, A., & Evins, A. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30272-0 · Cited by 1,177
Self-citationPremature Mortality Among Adults With Schizophrenia in the United States
Olfson, M., Gerhard, T., Huang, C., Crystal, S., & Stroup, T. S. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1737 · Cited by 1,083 · cited 4×
“The results notably replicate consistent reports of very low abstinence rates of approximately 4% for smokers with PDs with behavioral treatment (and placebo) alone.3 Low abstinence rates with behavioral treatment alone, combined with underutilization of effective smoking cessation pharmacotherapy,13,22 may underlie t…”
InfluentialPirie, K., Peto, R., Reeves, G. K., Green, J., & Beral, V. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61720-6 · Cited by 799
Cook, B. L., Wayne, G. F., Kafali, E. N., Liu, Z., Shu, C., & Flores, M. (2014) · JAMA · doi:10.1001/jama.2013.284985 · Cited by 519
McClave, A. K., McKnight-Eily, L. R., Davis, S. P., & Dube, S. R. (2010) · American Journal of Public Health · doi:10.2105/ajph.2009.188136 · Cited by 339
Smoking and mental illness in the US population
Smith, P. H., Mazure, C. M., & McKee, S. A. (2014) · Tobacco Control · doi:10.1136/tobaccocontrol-2013-051466 · Cited by 323
Interventions for smoking cessation and reduction in individuals with schizophrenia
Tsoi, D. T., Porwal, M., & Webster, A. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007253.pub3 · Cited by 304
Cited by
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
Treatment of Tobacco Smoking: A Review
Rigotti, N. A., Kruse, G. R., Livingstone-Banks, J., & Hartmann-Boyce, J. (2022) · JAMA · doi:10.1001/jama.2022.0395 · Cited by 361
Antidepressants for smoking cessation
Hajizadeh, A., Howes, S., Theodoulou, A., Klemperer, E., Hartmann-Boyce, J., Livingstone-Banks, J., & Lindson, N. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub6 · Cited by 84
Daumit, G. L., Evins, A. E., Cather, C., Dalcin, A. T., Dickerson, F. B., Miller, E. R., Appel, L. J., Jerome, G. J., McCann, U., Ford, D. E., et al. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.1691 · Cited by 13
Self-citationAnthenelli, R. M., McKenna, B. S., Giannini, J., Attaluri, S. V., Rubin, M., O’Crowley, E., Miller, S., & Heffner, J. L. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.111012 · Cited by 2
Self-citation
Metadata
- Authors
- Evins, A. E., Benowitz, N. L., West, R., Russ, C., McRae, T., Lawrence, D., Krishen, A., St Aubin, L., Maravic, M. C., & Anthenelli, R. M.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2019-03
- Volume
- 39
- Issue
- 2
- Pages
- 108-116
- ISSN
- 0271-0749 (ISSN-L)
- 1533-712X
- OpenAlex
- W2916429144
- Cited by
- 98
- References
- 18
- FWCI
- 8.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial. https://app.cochat.ai/papers/10.1097/jcp.0000000000001015
- The paper
- Evins, A. E., Benowitz, N. L., West, R., Russ, C., McRae, T., Lawrence, D., Krishen, A., St Aubin, L., Maravic, M. C., & Anthenelli, R. M. (2019). Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000001015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.